(Q35575047)

8 August 2017

1 reference

title

The role of Pemetrexed (Alimta , LY231514) in lung cancer therapy (English)

1 reference

8 August 2017

The Role of Pemetrexed (Alimta®, LY231514) in Lung Cancer Therapy (English)

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.017

28 March 2024

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.017

28 March 2024

1

Julian R Molina

1 reference

8 August 2017

Alex A. Adjei

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14596699

28 March 2024

language of work or name

English

0 references

publication date

1 July 2003

1 reference

full work available at URL

8 August 2017

https://api.elsevier.com/content/article/PII:S1525730411703163?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.017

https://api.elsevier.com/content/article/PII:S1525730411703163?httpAccept=text/plain

28 March 2024

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.017

28 March 2024

1 reference

8 August 2017

volume

5

1 reference

8 August 2017

issue

1

1 reference

8 August 2017

page(s)

21-27

1 reference

8 August 2017

1

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.017

Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology

28 March 2024

2

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.017

New prognostic indicator for non-small-cell lung cancer, quantitation of thymidylate synthase by real-time reverse transcription polymerase chain reaction

28 March 2024

3

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.017

Chemotherapy with 5-fluorouracil (5-FU) and cisplatin or 5-FU, cisplatin, and vinblastine for advanced non-small cell lung cancer. A randomized phase II study of the cancer and leukemia group B.

28 March 2024

4

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.017

A phase III study of radiotherapy with and without continuous-infusion fluorouracil as palliation for non-small-cell lung cancer

28 March 2024

5

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.017

Raltitrexed (Tomudex): an alternative choice in patients intolerant to 5-fluorouracil

28 March 2024

6

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.017

Phase II study of Edatrexate in stage III and IV non-small-cell lung cancer

28 March 2024

7

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.017

Improved Therapeutic Index by Leucovorin of Edatrexate, Cyclophosphamide, and Cisplatin Regimen for Non-Small-Cell Lung Cancer

28 March 2024

8

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.017

Design and synthesis of inhibitors of folate-dependent enzymes as antitumor agents.

28 March 2024

9

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.017

28 March 2024

Fluorinated pyrimidines

13

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.017

Glutamyl hydrolase and the multitargeted antifolate LY231514.

28 March 2024

15

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.017

LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes

28 March 2024

16

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.017

Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation

28 March 2024

19

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.017

A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation.

28 March 2024

20

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.017

Metabolic abnormalities in cobalamin (vitamin B12) and folate deficiency.

28 March 2024

21

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.017

Laboratory diagnosis of vitamin B12 and folate deficiency: a guide for the primary care physician

28 March 2024

22

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.017

The B vitamins and vitamin C in human nutrition. I. General considerations and 'obligatory' B vitamins

28 March 2024

23

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.017

Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group

28 March 2024

27

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.017

Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naïve patients with advanced non-small-cell lung cancer

28 March 2024

28

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.017

Chemotherapy of lung cancer

28 March 2024

29

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.017

ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study

28 March 2024

30

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.017

Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin

28 March 2024

32

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.017

Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors

28 March 2024

34

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.017

Open label, multi-centre phase II study of raltitrexed ('Tomudex') in patients with inoperable squamous-cell carcinoma of head and neck

28 March 2024

36

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.017

Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial

28 March 2024

37

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.017

Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group

28 March 2024

38

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.017

Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma

28 March 2024

39

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.017

A phase I trial of MTA and gemcitabine in patients with locally advanced or metastatic cancer

28 March 2024

41

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.017

Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma

28 March 2024

42

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.017

28 March 2024

Identifiers

1 reference

release_pzo73origzc5lf7wjxmekug7n4

8 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/pzo73origzc5lf7wjxmekug7n4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference